Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 17, 2016 - Issue 7
Submit an article Journal homepage
649
Views
19
CrossRef citations to date
0
Altmetric
Drug Evaluation

Rociletinib, a third generation EGFR tyrosine kinase inhibitor: current data and future directions

Jody C. ChuangDivision of Hematology and Oncology, Stanford Hospital & Clinics, Stanford, CA, USA
,
Ameen A. SalahudeenDivision of Hematology and Oncology, Stanford Hospital & Clinics, Stanford, CA, USA
&
Heather A. WakeleeDepartment of Medicine, Division of Oncology, Stanford University School of Medicine, Stanford, CA, USACorrespondence[email protected]
Pages 989-993 | Received 22 Dec 2015, Accepted 03 Mar 2016, Published online: 04 Apr 2016

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.